A Study to Assess the Efficacy and Safety of HMI-115 in Subjects with Endometriosis-Associated Pain

Description

This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.

Conditions

Endometriosis

Study Overview

Study Details

Study overview

This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period

A Study to Assess the Efficacy and Safety of HMI-115 in Subjects with Endometriosis-Associated Pain

Condition
Endometriosis
Intervention / Treatment

-

Contacts and Locations

Draper

Physicians' Research Options, LLC- Corner Canyon Clinic, Draper, Utah, United States, 84020

Norfolk

Tidewater Clinical Research/TPW, Norfolk, Virginia, United States, 23502

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Pre-menopausal female subjects, between 18 and 49 years of age, inclusive, at the time of signing informed consent.
  • 2. Subject must have a clinical diagnosis of endometriosis (laparoscopy or laparotomy) as documented by medical records within 10 years before screening.
  • 3. Subject must have a Composite Pelvic Signs and Symptoms Score total score of ≥ 6 with a score of at least 2 for DYS and at least 2 for NMPP at screening.
  • 4. Subject agrees not to participate in another interventional study while participating in the present study.
  • 1. Subject is pregnant or breastfeeding or is planning a pregnancy during the study period.
  • 2. Subject has chronic pelvic pain that is not caused by endometriosis or has any other chronic pain syndrome or other chronic therapy, or that would interfere with the assessment of endometriosis-related pain
  • 3. Subject has clinically significant gynecologic condition other than endometriosis
  • 4. Subject has previous history of a severe, life-threatening or other significant sensitivity to any opioids or non-steroidal anti inflammatory drugs (NSAIDS) or any contraindication to their use such as gastrointestinal ulcer or bleeding
  • 5. Subject has history of hysterectomy and/or bilateral oophorectomy
  • 6. Subjects with past or present pituitary tumor growth
  • 7. Subjects has a history of osteoporosis or other metabolic bone disease

Ages Eligible for Study

18 Years to 49 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Hope Medicine (Nanjing) Co., Ltd,

Study Record Dates

2025-04